Clinical trials: Relapsing Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
This was an open-label, multicentric, prospective, post-marketing surveillance (PMS) study on the extent to which subject compliance is influenced by use of a variable titration regimen at the start of treatment of relapsing MS…
- Trial name
- TOURIMS (NCT01142492)
- Testing
- Interferon beta-1a
- Volunteers
- 403 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
In the course of therapy escalation, the multiple sclerosis (MS) subjects with high activity of disease receive mainly mitoxantrone.
- Trial name
- REMAIN (NCT01142466)
- Testing
- Interferon beta-1a (Rebif)
- Volunteers
- 30 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis (MS) - Relapsing-remitting
Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor
The purpose of this study is to determine the safety and tolerability of the drug sirolimus in patients with multiple sclerosis (MS) who have failed other treatments.
- Trial name
- NCT00095329
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Relapsing-Remitting
Phase I BP Interferon (IFN) Beta-001
Phase I study aiming at: assessing the absolute bioavailability, pharmacokinetic profile, and dose proportionality of interferon beta-1a (HSA-free solution in pre-filled syringes) after i.v. and s.c.
- Trial name
- NCT02515695
- Testing
- Interferon beta-1a
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Relapsing Remitting Multiple Sclerosis
An Extension of the TG1101-RMS201 Trial
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
- Trial name
- NCT03381170
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- TG Therapeutics, Inc.
Relapsing Multiple Sclerosis
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
We aim to assess the effect of Ofatumumab on microglial activation using [F-18]PBR06 PET in MS patients in relation to changes in serum markers, MRI abnormalities and clinical impairment longitudinally over 9 months.
- Trial name
- NCT04510220
- Testing
- Ofatumumab, [F-18]PBR06
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brigham and Women's Hospital
Multiple Sclerosis, Relapsing-Remitting
Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis
This study is designed to compare two non-myeloablative conditioning regimens (combination of chemotherapy and immune specific proteins against immune cells) for relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT05482542
- Testing
- Autologous hematopoietic stem cell transplantation, Cyclophosphamide/ATG, Cyclophosphamide/Rituximab
- Where
- United States
- Sponsor
- Scripps Health
Relapsing-Remitting Multiple Sclerosis
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
The primary objective of this study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (PBH) over 52 weeks.
- Trial name
- REVEAL (NCT02342704)
- Testing
- natalizumab, fingolimod
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis
Little is known about the potential effects of exercise on the underlying disease mechanisms in multiple sclerosis (MS). Although contactin-1 and contactin-2 are known as two proteins involved in axonal regeneration, it is…
- Trial name
- NCT05351411
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Firat University
Relapsing Remitting Multiple Sclerosis
Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis
In this Phase 1b open-label prospective clinical trial, patients with relapsing-remitting MS will undergo FMT of FMP30 (donor stool) via colonoscopy and immunological efficacy endpoints will be assessed at various time points.
- Trial name
- MS-BIOME (NCT03594487)
- Testing
- FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Jeffrey Gelfand
Multiple Sclerosis
An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis.
- Trial name
- NCT00670449
- Testing
- Fingolimod
- Where
- 20 sites in Japan
- Volunteers
- 143 people
- Sponsor
- Novartis
Multiple Sclerosis
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
This study is a randomized multicentre, multinational, treatment interventional study of RRMS patients with breakthrough inflammatory disease activity in spite of ongoing standard immunomodulatory medication.
- Trial name
- RAM-MS (NCT03477500)
- Testing
- Cyclophosphamide and ATG, Alemtuzumab, Cladribine Pill
- Where
- 8 sites in Denmark, Netherlands and 2 more
- Volunteers
- 100 people
- Sponsor
- Haukeland University Hospital
Multiple Sclerosis
Safety Study of GNbAC1 in Multiple Sclerosis Patients
The purpose of this study is to assess the safety and tolerability of single ascending doses, as well as of repeated administrations of GNbAC1 in MS patients.
- Trial name
- NCT01639300
- Testing
- GNbAC1
- Where
- 2 sites in Switzerland
- Volunteers
- 10 people
- Sponsor
- GeNeuro Innovation SAS
Multiple Sclerosis, Relapsing-Remitting
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
Significant data from placebo-controlled clinical trials have demonstrated the efficacy of Rebif in relapsing remitting multiple sclerosis (RRMS) with reduction in relapse rate, delay in disability progression, and reduction in…
- Trial name
- COMPARE (NCT01141751)
- Volunteers
- 334 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse…
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT05663853
- Where
- 4 sites in United States
- Volunteers
- 137 people
- Sponsor
- LAPIX Therapeutics Inc.
Multiple Sclerosis
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
We are studying this investigational drug treatment, comparing it with placebo, to evaluate whether it is effective in reducing the number of MRI lesions with a minimum number of side effects.
- Trial name
- NCT00079495
- Testing
- NBI-5788
- Volunteers
- 150 people
- Sponsor
- Neurocrine Biosciences
Multiple Sclerosis
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
In this study, researchers will learn more about the effects of diroximel fumarate (DRF), also known as VUMERITY®, when taken during pregnancy in people with multiple sclerosis, also known as MS.
- Trial name
- NCT05688436
- Testing
- Diroximel Fumarate, Alemtuzumab, Fingolimod
- Where
- United States
- Volunteers
- 1,178 people
- Sponsor
- Biogen
Multiple Sclerosis, Cognitive Impairment
Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis
This study is a cross sectional study of patients diagnosed with clinically isolated syndrome (CIS) and RRMS, who will undergo a series of tests to assess cognitive impairment, fatigue severity and depressive symptoms.
- Trial name
- NCT01250665
- Where
- Switzerland
- Volunteers
- 65 people
- Sponsor
- Cantonal Hospital of St. Gallen
Relapsing Remitting Multiple Sclerosis
Mechanistic Studies of Teriflunomide in RRMS
This study is to address the mechanism of action of teriflunomide in a phase IV open label trial with Teriflunomide in multiple sclerosis.
- Trial name
- NCT03464448
- Testing
- Teriflunomide
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Multiple Sclerosis
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
- Trial name
- NCT02576717
- Testing
- RPC1063
- Where
- 175 sites in United States, Belarus and 24 more
- Volunteers
- 2,494 people
- Sponsor
- Celgene